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Abstract
Tumor immunosuppression is commonly braided with chronic inflammation during tumor development. However, the
relationship between immunosuppression and inflammation in tumor microenvironment is still unclear. We have
demonstrated that mast cells are accumulated and exacerbate the inflammation and immunosuppression in tumor
microenvironment via SCF/c-kit signaling pathway. Here, we further elucidate the underlying mechanism, which involves
both myeloid-derived suppressor cells (MDSCs) and regulatory T (Treg) cells. Our data showed that mast cells mobilized the
infiltration of MDSCs to tumor and induced the production of IL-17 by MDSCs; MDSCs-derived IL-17 indirectly attracted Treg
cells, enhanced their suppressor function, and induced the IL-9 production by Treg cells; in turn, IL-9 strengthened the
survival and protumor effect of mast cells in tumor microenvironment. Our findings disclose a closed loop among mast cells,
MDSCs and Treg cells in tumor microenvironment, which provides a new insight into the paralleled developments of
inflammation and immunosuppression in tumor microenvironment. Based on these findings, we propose that targeting
tumor inflammation might be a potential strategy to reverse the immunosuppression of tumor microenvironment, thus
facilitating cancer immunotherapy.
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Introduction
A major challenge for cancer immunotherapy comes from the
tumor-induced immunosuppression, which dampens cytotoxic
activities of T lymphocytes and natural killer (NK) cells [1,2].
Various immunosuppressive ways are exploited by tumors.
However, why tumors have such versatile abilities to build an
immunosuppressive microenvironment is still incompletely under-
stood. During tumor development, tumor immunosuppression is
commonly braided with ‘‘smoldering’’ inflammation [3,4]. The
latter probably is the driving force. Like normal tissues, tumors
also need immune regulation to avoid the catastrophic damage
from the uncontrolled inflammation. Therefore, in response to
smoldering inflammation of tumors, multiple immunosuppressive
cell types are mobilized to tumor. Among them, Treg cells and
MDSCs are pivotal [5,6].
Treg cells are distinct lymphocyte lineage endowed with
regulatory properties in maintaining immunological tolerance.
The expression of transcription factor Foxp3 is the most distinctive
marker for Treg cells [7]. MDSCs are a heterogeneous population
of immature myeloid cells originated from bone marrow [8,9].
MDSCs in mouse are marked by Gr-1 and CD11b or more
specifically by Gr-1 and CD115 (M-CSFR) [10]. Both Tregs and
MDSCs may be directly involved in immune unresponsiveness via
multiple mechanisms. The means by which Treg cells suppress
tumor-specific T cells includes 1) secretion of suppressor cytokines
IL-10 and TGF-b [11]; 2) suppression of the function of APC
through CTLA4 pathway [12]; 3) hydrolysis of extracellular ATP
to inhibitory adenosine by CD39 and CD73 [13]; and 4)
transferring inhibitory cAMP from Treg cells to effector T cells
through gap junction [14]. On the other hand, MDSCs are
capable of inhibiting effector T cells by: 1) IFN-c-dependent nitric
oxide (NO) production [15]; 2) IL-4-dependent arginase 1
synthesis [16]; 3) inducing the loss of CD3f signaling [17]; 4)
suppression of the T-cell response through reactive oxygen species
[18–20]; and 5) mediating the development of Treg cells [10].
Regardless of such well defined immunosuppressive effects, it is
unclear how Treg cells and MDSCs communicate with each
other, and how tumor-infiltrating Treg cells and MDSCs are
regulated in tumor microenvironment. In addition, MDSCs are
reported to be related to inflammation [21–23]. However, whether
MDSCs may directly contribute to tumor inflammation remains
unknown.
Mast cells are critical innate immune cell type, which can also
function as immune regulatory cells [24,25]. We recently
demonstrated that mast cells were accumulated in tumor
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exacerbation of the inflammation and immunosuppression in
tumor microenvironment [26]. In this study, we further investi-
gated the mechanism by which mast cells mediate tumor
inflammation and immunosuppression. We found that mast cells
mobilized the infiltration of MDSCs to tumor and induced the
production of IL-17 by MDSCs; MDSCs-derived IL-17 indirectly
attracted Treg cells, enhanced their suppressor function, and
induced the IL-9 production by Treg cells; in turn, IL-9
strengthened the survival and protumor effect of mast cells in
tumor microenvironment. Thus, these findings indicate an
intrinsic relationship among mast cells, MDSCs and Treg cells
in tumor microenvironment.
Results
Regulation of Tumor-Infiltrating MDSCs by Mast Cells
We previously demonstrated that bone marrow-derived mast
cells (BMMCs) effectively migrate to H22 hepatocarcinoma cell
line-inoculated tumor site after tail vein injection [26]. Using this
model, we initially examined the influence of mast cells on tumor-
infiltratingMDSCs.BMMCswereinjectedintoH22tumor-bearing
mice (565 mm). Seven days later, we analyzed the tumor-infiltrated
Gr-1
+CD11b
+ MDSCs, and found that the proportion of MDSCs
in tumor was significantly increased in BMMC group, compared to
bone marrow cell control group (Fig. 1A). To exclude the
contamination by MDSCs, we additionally labeled BMMCs with
CFSE and injected cells to mice. The flow cytometric analysis
indicated that the CFSE
+ cells didnot express MDSC’s markers Gr-
1 and CD11b (data not shown), suggesting no MDSC contamina-
tionduringadoptivetransferofBMMCs.Todeterminethefunction
of MDSCs, we isolated tumor MDSCs for suppression assay. We
found that the injection of BMMCs enhanced the suppressor
function of MDSCs on T cell proliferation (Fig. 1B). Our previous
study showed that SCF/c-kit signaling is critical for the protumor
effect of mast cells [26]. In line with this, we here also found that
SCF neutralization or c-kit blockade impaired the effect of BMMCs
on MDSCs (Fig. 1, A and B).
To explain the above effect of BMMCs on MDSCs, we
selectively analyzed several factors relative to the migration and
function of MDSCs, and found that the injection of BMMCs
increased chemokine CCL2 level in tumor and upregulated
arginase 1 expression in MDSCs (Fig. 1, C–E). In addition, the
levels of IL-10 and IL-13 were also increased in tumor after
BMMC injection (Fig. 1, C and D). Interestingly, the addition of
either IL-10 or IL-13 upregulated arginase 1 expression in the in
vitro cultured MDSCs (Fig. 1E), consistent with the previous report
of upregulation of arginase 1 by Th2 cytokines [16]. CCL2
signaling has been reported to mediate the migration of MDSCs
[27] and arginase 1 is an important pathway for mediating the
suppressor function of MDSCs [28]. Therefore, mast cells
probably promote the migration and suppressor function of tumor
MDSCs by regulating the expressions of CCL2 and Th2
cytokines.
Mast Cells Regulate MDSCs through IL-17 Pathway and
Induce IL-17 Expression in MDSCs
Considering that the inflammation is capable of regulating
CCL2 and Th2 cytokines and mast cells are the key inflammatory
cells, we speculated that inflammation pathway was involved in
mast cells-mediated regulation of MDSCs. Interestingly, IL-17, a
critical inflammatory cytokine [29], was reported to be upregu-
lated by mast cells in tumor microenvironment [26]. In this
context, we wondered whether mast cells regulated MDSCs
through IL-17 pathway. To test this, we injected BMMCs into
Figure 1. The regulation of tumor-infiltrating MDSCs by mast cells. (A) Mast cells promoted the infiltration of MDSCs into tumor
microenvironment. 5610
6 BMMCs with or without anti-SCF or c-kit antibodies, were injected into tumor-bearing mice by i.v. injection. Bone marrow
cells were used as control. Seven days later, the tumor-infiltrating lymphocytes were used to analyze Gr-1
+CD11b
+ MDSCs by flow cytometry. The left
shown was the representative of FACS profiles. The right shown was the combined reproducible data (n=6). *, P,0.05, compared to control. (B) Mast
cells promoted the suppressive function of MDSCs in tumor microenvironment. BMMCs with or without antibodies, were injected into tumor-bearing
mice (n=6). Seven days later, tumor-infiltrating MDSCs were isolated as described in Materials and Methods and the suppression assay was performed
as described in Materials and Methods. (C and D) Mast cells upregulated the expressions of CCL2, IL-10 and IL-13 in tumor microenvironment. BMMCs
were injected into tumor-bearing mice. Seven days later, tumor tissues were used to analyze CCL2, IL-10 and IL-13 expressions by real time RT-PCR (C)
and ELISA (D). (E) The regulation of arginase 1 by mast cells. Lane 1–2: tumor tissues from BMMC group or control were used to analyze arginase 1
expression by real time-RT-PCR and western blot. Lane 3–5: the cultured MDSCs were treated with PBS or IL-10 (20 ng/ml) or IL-13 (20 ng/ml) for
48 h, and then used for the analysis of arginase 1 expression.
doi:10.1371/journal.pone.0008922.g001
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administrated at different times after BMMCs injection. We found
that the blockade of IL-17 with the antibody prevented BMMCs-
mediated MDSC infiltration to tumor and decreased the
suppressive activity of MDSCs (Fig. 2, A and B), suggesting that
mast cells regulate MDSCs through IL-17 pathway. We then
investigated the cellular source of IL-17 induced by BMMCs. We
isolated tumor cells from tumor tissue for the intracellular staining.
IL-17
+ tumor cells were not detectable (Fig. 2C). Although Th17
cells are considered as the main cell type for IL-17 production, in
our tumor model, we found that few CD3
+ T cells expressed IL-17
(Fig. 2C). Meanwhile, IL-17 was not expressed by CD19
+ cells
(Fig. 2C). Therefore, IL-17 might be expressed by innate immune
cells. We have reported IL-17 expression by CD11b
+ cells in
inflammatory allergic lung tissue [30]. In line with this, we found
that BMMCs augmented CD11b
+ cells expressing IL-17 in tumor
microenvironment (Fig. 2D). Further analysis confirmed that most
IL-17
+CD11b
+ cells were Gr-1 positive, and Gr-1
+CD11b
+
MDSCs were the main cellular source of IL-17 in tumor
microenvironment (Fig. 2E). Thus, these data disclosed an
unknown role of MDSCs in that MDSCs migrate to tumor site
and participate in tumor inflammation by producing IL-17 in
response to the remodeled tumor inflammation by mast cells.
Regulation of Treg Cells by Mast Cells in Tumor
Microenvironment
Next, we investigated the influence of mast cells on tumor-
infiltrating Treg cells. Seven days after the i.v. injection of
BMMCs, the frequency of Treg cells in tumor microenvironment
was significantly increased (12.2% versus 18.7%, Fig. 3A); and the
suppression of Treg cells on T cell proliferation was also enhanced
(Fig. 3B). Consistently, the prevention of BMMC migration to
tumor by either SCF neutralization or c-kit blockade resulted in
the no effect of BMMCs on Treg cells (Fig. 3, A and B). Therefore,
these data suggested that mast cells regulate the infiltration and
suppressor function of Treg cells in tumor microenvironment.
Mast Cell-Induced IL-17 Mediates Treg Cell Infiltration via
Upregulating Chemokines CCL17 and CCL22
Migration of Treg cells to inflammation site might be to avoid
the catastrophic damage from the uncontrolled inflammation by
suppressing immune responses. In this regard, we speculated that
mast cell-exacerbated tumor inflammation facilitated Treg cell
infiltration. To test this, we here concentrated on IL-17. The
neutralization of IL-17 resulted in the no effect of BMMCs on
Treg cell infiltration (Fig. 4A), Since MDSCs was the cellular
source of IL-17 in this tumor model, we therefore depleted
MDSCs by i.p. injection of anti-Gr-1 depleting antibody [31] or
i.p. injected anti-CCL2 neutralizing antibody to inhibit MDSC
migration to tumor [27]. Consistently, we found that either
MDSC depletion or migration blockade blunted the effect of
BMMCs on Treg cell infiltration (Fig. 4A). These data suggested
that BMMCs exert its effect on Treg cells through IL-17 pathway.
Next, we investigated the underlying mechanism by which
BMMCs-induced IL-17 facilitated Treg cell infiltration. We paid
the attention on chemokines CCL17 and CCL22, the selective
chemoattractants for Treg cells [32–34]. We found that BMMC
injection increased the expression of CCL17 and CCL22 in tumor
microenvironment, evaluated by real time RT-PCR (Fig. 4B),
which could be blunted by IL-17 neutralization or blocking
MDSC migration (Fig. 4B). A consistent result was observed by
analyzing the protein levels of CCL17 and CCL22 by ELISA
(Fig. 4C). Furthermore, the neutralization of CCL17 or CCL22
could prevent Treg cell infiltration to tumor (Fig. 4D). Therefore,
Figure 2. Mast cells regulate MDSCs through IL-17 pathway. (A) Blockade of IL-17 prevented mast cell-mediated MDSC infiltration to tumor.
5610
6 BMMCs were injected into tumor-bearing mice by i.v. injection. IL-17 neutralizing antibody was i.p. injected to the mice 1 h, 2 days and 5 days
after BMMCs injection. On day 7, the tumor-infiltrating lymphocytes were used to analyze Gr-1
+CD11b
+ MDSCs by flow cytometry (left). In addition,
IL-17 neutralizing antibody was i.p. injected to the mice 24 h and 1 h before BMMCs injection. 2610
6 CFSE-labeled MDSCs were injected into the
mice two days later. The tumor tissues were surgically excised, and frozen sections were prepared and analyzed by fluorescence microscopy (right).
(B) Blockade of IL-17 attenuated mast cell-mediated MDSC suppressive function. BMMCs were injected into tumor-bearing mice. IL-17 neutralizing
antibody was i.p. injected to the mice at different time points. On day 7, tumor-infiltrating MDSCs were isolated for the suppression assay. (C) IL-17
was not expressed by H22 tumor cells, T cells or B cells. BMMCs were injected into tumor-bearing mice. Seven days later, tumor cells and TILs were
isolated, respectively. The expression of IL-17 was analyzed by flow cytometry. (D and E) Mast cells upregulated the expression of IL-17 by MDSCs.
Seven days after BMMCs injection, the isolated TILs were used for IL-17 expression analysis. The data showed the upregulation of IL-17 by CD11b
+
cells in BMMC group (D), and most of the gated IL-17
+ cells expressed Gr-1 marker (E).
doi:10.1371/journal.pone.0008922.g002
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of Treg cells. 5610
6 BMMCs with or without anti-SCF or c-kit antibodies, were injected into tumor-bearing mice by i.v. injection. Bone marrow cells
were used as control. Seven days later, the tumor-infiltrating lymphocytes were used to analyze CD3
+Foxp3
+ Treg cells by flow cytometry. The left
shown was the representative of FACS profiles. The right shown was the combined reproducible data (n=6), *, P,0.05, compared to BM cell control.
(B) Mast cells regulate the suppressive function of Treg cells. BMMCs with or without antibodies, were injected into tumor-bearing mice (n=6). Seven
days later, tumor-infiltrating Treg cells were isolated as described in Materials and Methods and the suppression assay was performed as described in
Materials and Methods.
doi:10.1371/journal.pone.0008922.g003
Figure 4. Mast cell-induced IL-17 mediates Treg cell infiltration via upregulating chemokines CCL17 and CCL22. (A) The interference
of IL-17 impaired the effect of mast cells on Treg cell infiltration. 5610
6 BMMCs were injected into tumor-bearing mice by i.v. injection. IL-17 or CCL2
neutralizing antibody or Gr-1 depleting antibody was i.p. injected to the mice 1 h, 2 days and 5 days after BMMCs injection. On day 7, the tumor-
infiltrating lymphocytes were isolated to analyze CD3
+Foxp3
+ Treg cells by flow cytometry. The results were combined from three mice. (B and C)
Mast cells-induced IL-17 upregulated CCL17 and CCL22 expressions in tumor microenvironment. BMMCs were injected into tumor-bearing mice. IL-
17 or Gr-1 antibody was i.p. injected to the mice at different time points. Seven days after BMMCs injection, the tumor tissues were used to analyze
CCL17 and CCL22 expressions by real time RT-PCR (B) and ELISA (C). (D) The effect of CCL17 and CCL22 on Treg cell infiltration. BMMCs were injected
into tumor-bearing mice. CCL17 or CCL22 neutralizing antibody was i.p. injected to the mice 1 h, 2 days and 5 days after BMMCs injection. On day 7,
the tumor-infiltrating lymphocytes were isolated to analyze CD3
+Foxp3
+ Treg cells by flow cytometry. The results were combined from three mice.
doi:10.1371/journal.pone.0008922.g004
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CCL22 in tumor microenvironment, which then chemoattracted
Treg cells to tumor.
Mast Cell-Induced IL-17 Enhances Suppressor Function of
Treg Cells via Upregulating CD39 and CD73
Besides its effect on Treg cell infiltration, we also found that IL-
17 affected the suppressive function of Treg cells in tumor
microenvironment. IL-17 neutralization effectively blunted the
effect of BMMCs on Treg cell function (Fig. 5A). A consistent
result was observed, if depleting MDSCs or blocking MDSC
migration (Fig. 5A). Therefore, MDSC-derived IL-17 enhanced
the suppressive function of Treg cells. Here, we further studied the
molecular basis. We wondered whether inhibitory molecule
CTLA4 expressed by Treg cells was the reason. However, the
flow cytometric analysis did not show the different expression of
CTLA4 between BMMC group and control (Fig. 5B). In addition,
the enhanced suppressive function seemed not be explained by
inhibitory cytokines IL-10 and TGF-b, since their mRNA levels
were not altered in Treg cells evaluated by real time RT-PCR
analysis (Fig. 5C). Recently, ectoenzymes CD39 and CD73 were
demonstrated to play important role in Treg cell suppressive
function through hydrolyzing nucleotide to adenosine, leading to
immune inhibitory signal transduction via adenosine receptor A2A
[13,35]. Here, we found that BMMC injection upregulated the
expressions of CD39 and CD73 in Treg cells and IL-17
neutralization impaired this effect (Fig. 5D). Interestingly, in vitro
study showed that IL-17 had no effect on Treg cells expressing
CD39 and CD73 (Fig. 5E), suggesting an indirect effect of IL-17
on Treg cells in vivo. To address whether the increased CD39 and
CD73 enhanced the suppressive function of Treg cells, we used
adenosine receptor A2A antagonist SCH-58261 for the in vitro
suppression assay, since adenosine is the hydrolytic product of
CD39 and CD73 and mediates the immunosuppression [13]. As
expected, blocking adenosine pathway attenuated the suppressive
function of Treg cells enhanced by BMMC injection (Fig. 5F).
Taken together, these data suggested that IL-17 induced by mast
cells leads to Treg cells upregulating CD39 and CD73 expression
for an enhanced suppressive function in tumor microenvironment.
The Production of IL-9 by Treg Cells Is Required for Mast
Cell-Mediated Protumor Effect in Tumor
Microenvironment
Given that Treg cells produce IL-9 for immune suppression
through the activation of mast cells in an allograft model [36], and
that IL-9 plays an important role in mast cell survival, we here
further speculated that the involvement of IL-9 by Treg cells in
mast cell-mediated tumor promotion. Three days after BMMC
injection, the upregulation of IL-9 in Treg cells was observed,
evaluated by real time RT-PCR and ELISA analysis (Fig. 6, A and
B). However, the neutralization of IL-17 or depletion of MDSCs
blunted such upregulation (Fig. 6, A and B), suggesting that mast
cells enhance Treg cells expressing IL-9 via IL-17 signaling
pathway in tumor microenvironment. Next, we examined the
Figure 5. Mast cell-induced IL-17 enhances suppressor function of Treg cells via upregulating CD39 and CD73. (A) The interference of
IL-17 impaired the effect of mast cells on the suppressive function of Treg cells. 5610
6 BMMCs were injected into tumor-bearing mice by i.v. injection.
IL-17 or CCL2 neutralizing antibody or Gr-1 depleting antibody was i.p. injected to the mice 1 h, 2 days and 5 days after BMMCs injection. On day 7,
tumor-infiltrating Treg cells were isolated for suppression assay. (B and C) Mast cells had no effect on Treg cells expressing CTLA-4, IL-10 or TGF-b.
BMMCs were injected into tumor-bearing mice. Seven days later, the tumor-infiltrating lymphocytes were isolated for the analysis of CTLA-4 by flow
cytometry. The data showed the gated CD3
+Foxp3
+ cells. (B) or IL-10 and TGF-b by real time RT-PCR (C). (D) Mast cells upregulated the expressions of
CD39 and CD73 by Treg cells. BMMCs were injected into tumor-bearing mice with IL-17 antibody or control antibody. Seven days later, the tumor-
infiltrating Treg cells were isolated for the analysis of CD39 and CD73 by real time RT-PCR and western blot. (E) IL-17 had no direct effect on Treg cells.
IL-17 (20 ng/ml) was added to the cultured Treg cells for 12 hours. The cells were collected for the analysis of CD39 and CD73 by real time RT-PCR. F,
Blockade of adenosine signaling pathway impaired mast cell-enhanced Treg cell function. BMMCs were injected into tumor-bearing mice. BM cells
were used as control. Seven days later, the tumor-infiltrating Treg cells were isolated for suppression assay in the presence or absence of adenosine
receptor A2A antagonist SCH-58261 (100 ng/ml). The data shown were the representative of 2 independent experiments in which the similar results
were obtained.
doi:10.1371/journal.pone.0008922.g005
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by either IL-9 neutralizing antibody or depleting Treg cells
weakened BMMCs-mediated MDSC infiltration toward tumor
(Fig. 6C), and attenuated BMMCs-enhanced tumor growth
(Fig. 6D). Moreover, the neutralization of IL-9 decreased the
survival time of BMMCs in tumor microenvironment (Fig. 6E).
Taken together, these data suggested that cytokine IL-9 by Treg
cells plays an important role in mast cell-mediated tumor
promotion in tumor microenvironment.
Discussion
In our previous study, we demonstrated that mast cells
infiltrating into tumor exerts a protumor effect by exacerbating
the inflammation and immunosuppression in tumor microenvi-
ronment [26]. Here, we further elucidate the underlying
mechanism, which involves two critical regulatory cell types: Treg
cells and MDSCs.
The initiation and remodeling of tumor microenvironment still
remains unclear. Our unpublished data indicated that mast cells
may be recruited to tumor cell-inoculated site as early as two hours
after inoculation, which further emphasized that mast cells are a
key regulator for tumor microenvironment. To realize this, the
recruitment of MDSCs by mast cells via CCL2/CCR2 axis
probably is a crucial step. Mast cells have the potential to secrete
diverse biologically active products upon exposure to a variety of
immunological or nonimmunological stimuli [24,25]. Here, we
find that the activated mast cells remodel tumor inflammatory
microenvironment by upregulating CCL2, IL-10 and IL-13,
which are associated with the migration and function of MDSCs,
respectively. Recently, chemokines SDF-1 and CXCL5 have been
shown to play a role in MDSC migration to tumor microenvi-
ronment [37]. In our tumor model, however, BMMC injection did
not alter the expressions of SDF-1 and CXCL5 in tumor
microenvironment (data not shown). We previously reported that
CCL2 is generally expressed in various tumor types of both human
and mouse and CCR2 is expressed by MDSCs [27]. Movahedi et
al. also reported that CCR2 is a marker for MDSCs [38]. On the
basis of these findings, we propose that CCL2/CCR2 axis may be
an important signaling pathway for MDSC recruitment to tumor
microenvironment.
Besides effecting on tumor immune evasion, tumor-infiltrating
MDSCs may also employ other ways for tumor promotion. Yang
et al reported that MDSCs produce MMP9 for tumor angiogen-
esis [39]. In a breast cancer model, tumor-infiltrating MDSCs are
shown to favor tumor cell invasion and metastasis (37). In the
present study, we identify a new role of MDSCs in tumor
microenvironment by producing proinflammatory cytokine IL-17.
As a critical proinflammatory cytokine, IL-17 has attracted great
attention recently. IL-17 acts on a broad range of cells to induce
the expression of cytokines (IL-6, IL-8, GM-CSF, G-CSF),
chemokines, and metalloproteinases [40–43]. It also cooperates
with TLR ligands, IL-1b, and TNF-a to enhance inflammatory
reactions and stimulate the production of b-defensins and other
antimicrobial peptides [44]. Although we here did not elucidate
the molecular basis of the upregulation of IL-17 in MDSCs by
mast cells, we illuminated the influence of IL-17 on MDSCs and
Treg cells. And these findings may lead to a better understanding
on the relationship between inflammation and immune regulation.
IL-17 inducted by tumor-infiltrating mast cells may profoundly
mold the inflammatory microenvironment. To avoid the inflam-
mation-induced tissue damage, regulatory cells such as MDSCs
and Treg cells are recruited to tumor microenvironment by IL-17-
induced upregulation of chemokines CCL2, CCL17 and CCL22.
Furthermore, the suppressor functions of MDSCs and Treg cells
are enhanced by IL-17-upregulated IL-10 and IL-13 in tumor
microenvironment and CD39 and CD73 on Treg cells. Currently,
the role of IL-17 in tumor is controversial [45–50]. According to
our findings, we suggest a protumor role of IL-17 by remodeling
tumor microenvironment. In addition, our findings also suggest
that the inflammation and immunosuppression can be developed
in a parallel manner.
Regardless of the extensive study on Treg cells and MDSCs in
tumor immunology, the general question of how Treg cells and
MDSCs interact in tumor microenvironment still remains unclear.
The previous report indicated that MDSCs mediate the
development of Treg cells through IL-10 and IFN-c pathways
[10]. Our present study further sheds light on this issue. In tumor
microenvironment, MDSCs indirectly influence the migration and
activity of Treg cells by producing IL-17. On the other hand, Treg
cells producing IL-9 indirect influence MDSCs through IL-9-
affected mast cell pathway. Therefore, MDSCs and Treg cells may
interact through indirect ways in tumor microenvironment.
However, the direct interaction between MDSCs and Treg cells
needs further study.
Figure 6. IL-9 strengthens the survival and protumor effect of
mast cells in tumor microenvironment. (A and B) Mast cells
upregulated the expressions of IL-9 by Treg cells. BMMCs were injected
into tumor-bearing mice with IL-17 antibody or control antibody. Seven
days later, the tumor-infiltrating Treg cells were isolated for the analysis
of IL-9 by real time RT-PCR (A). Or the isolated Treg cells were cultured
for 48 hours. The supernatant was used for IL-9 ELISA assay (B). (C and
D) The interference of IL-9 signaling affected mast cell-mediated MDSC
infiltration and mast cell-promoted tumor growth. 5610
6 BMMCs were
injected into tumor-bearing mice (n=6) by i.v. injection. IL-9
neutralizing antibody or CD25 depleting antibody was i.p. injected to
the mice 1 h, 2 days and 5 days after BMMCs injection. On day 12, the
tumor-infiltrating lymphocytes were used to analyze Gr-1
+CD11b
+
MDSCs by flow cytometry (C), and the tumor growth was monitored by
measuring the length (L) and width (W) of tumors. The volume (V) of
the tumor was calculated by the formula V=(L6W2)/2 (D). (E) IL-9
affected the survival of mast cells in tumor microenvironment. 1610
6
CFSE-labeled BMMCs were directly injected into tumor tissue with
multiple injection sites. IL-9 neutralizing antibody was i.p. injected to
the mice 1 h, 2 days and 5 days after BMMCs injection. The tumor
tissues were surgically excised on day 7 for fluorescent analysis of
frozen sections.
doi:10.1371/journal.pone.0008922.g006
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closed loop among mast cells, MDSCs and Treg cells in tumor
microenvironment (Fig 7), which provides a new insight into the
relationship between inflammation and immunosuppression in
tumor microenvironment. Our study also implies that targeting
tumor inflammation might be a potential strategy to reverse the
immunosuppression of tumor microenvironment, thus facilitating
cancer immunotherapy.
Materials and Methods
Ethics Statement
All animal work was conducted according to relevant national
and international guidelines. For details please refer to subsection
entitled Animals and cell lines.
Animals and Cell Lines
BALB/c mice, 6 to 8-week-old, were purchased from Center of
Medical Experimental Animals of Hubei Province (Wuhan,
China) for studies approved by the Animal Care and Use
Committee of Tongji Medical College. Mouse hepatocarcinoma
tumor cell line H22 was purchased from the China Center for
Type Culture Collection (CCTCC, Wuhan, China), and cultured
according to the guideline.
Generation of Bone Marrow-Derived Mast Cells
Bone marrow cells were harvested from femurs of mice and
cultured in RPMI 1640 supplemented with 10% FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate, 1 mM HEPES, 50 mM2 -
ME, 100 U/ml penicillin, and 100 mg/ml streptomycin. The
cells were cultured in the presence of IL-3 and SCF (10 ng/ml
each, PeproTech, Rocky Hill, NJ), and the nonadherent cells
were passaged every 3 days. 4 weeks later, the purity of mast
cells was assessed by toluidine blue staining of cytocentrifuge
preparations. Mast cells were identified by their morphological
features and the presence of metachromatic granules. Only
those preparations containing .98% mast cells were used in our
studies and referred to as bone marrow-derived mast cells
(BMMCs).
Tumor Model
BALB/c mice were inoculated with H22 tumor cells by
subcutaneous injection of 2610
5 cells to the left flank. 12 days
later, the mice (n=6 per group) with tumor size of ,565m m
2
received 5610
6 BMMCs by i.v. injection. When indicated, the
mice received i.p. injection of 100 mg of goat-anti-mouse SCF
neutralizing antibody (IgG, R&D Systems, Minneapolis, MN) or
goat IgG isotype control 24 h and 1 h before BMMCs injection,
or received the i.v. injection of BMMCs mixed with 50 mg of rat
anti-mouse c-Kit blocking antibody (eBioscience, San Diego, CA)
or rat IgG2b isotype control.
In Vivo Depletion Assay
Treg cells were depleted in vivo by i.p. injection of 100 mgo f
anti-mouse CD25 antibody (PC61.5; eBioscience). MDSCs were
depleted in vivo by i.p. injection of 50 mg of anti-mouse Gr-1
antibody (RB6-8C5; eBioscience). To prevent the migration of
MDSCs, the mice received i.p. injection of 100 mg of goat-anti-
mouse CCL2 neutralizing antibody (IgG, R&D Systems, Min-
neapolis, MN).
Figure 7. A model of the closed loop among mast cells, MDSCs and Treg cells in tumor microenvironment. Under the guidance of SCF/
c-kit signaling, mast cells migrate to and are activated in tumor microenvironment; the activated mast cells release a panel of factors, leading to CCL2
production and IL-17 upregulation in MDSCs; CCL2 signaling recruits more MDSCs, leading to more IL-17 production; IL-17 strengthens tumor
inflammatory microenvironment, leading to the upregulation of IL-9, IL-10, IL-13, CCL17, CCL22, CD39 and CD73; IL-10 and IL-13 induce arginase 1
expression by MDSCs; CCL17 and CCL22 attract the migration of Treg cells; CD39 and CD73 enhance suppressor function of Treg cells; IL-9 produced
by Treg cells maintains the survival of mast cells; MDSCs release active MMP9, through which soluble SCF is generated, thus further facilitating the
migration and activation of mast cells.
doi:10.1371/journal.pone.0008922.g007
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Tumors were digested with collagenase and hyaluronidase for
1 h at 37uC. After grinding with semifrosted slides and lysis of
RBC, the dissociated cells were incubated on ice for 20 min, and
then spun down at 500 rpm for 1 min. The cell pellet was washed
and used as tumor cells. The suspension cells were underlaid with
5 ml of Lymphocyte-M solution, centrifuged (2,200 rpm for
20 minutes). Tumor-infiltrating lymphocytes (TILs) were harvest-
ed from the interface. Treg cells were isolated with Treg cell
isolation kit (Miltenyi Biotec, Auburn, CA). The Gr-1
+CD11b
+
cells were sorted as MDSCs under stringent gating conditions (97–
98% purity, BD FACSAriaTM cell sorter).
Analysis of MDSCs and Mast Cells in Tumor Tissues
BALB/c mice were inoculated with H22 tumor cells as above.
12 days later, 5610
6 BMMCs were injected into tumor-bearing
mice via tail vein, When indicated, the mice received i.p. injection
of 100 mg of goat-anti-mouse IL-17 neutralizing antibody (R&D
Systems, Minneapolis, MN) or isotype control 24 h and 1 h before
BMMCs injection. 2610
6 CFSE-labeled MDSCs isolated from
tumor-bearing mice bone marrow and spleen were injected into
the above mice two days after BMMCs injection. The tumor
tissues were surgically excised from mice 24 hours after the
injection, and frozen sections were prepared and analyzed by
fluorescence microscopy (2006, Leica DMI6000B, Wetzlar,
Germany), using HC Plans objective lens and a Leica DFC300
FX camera. Image acquisition and processing were performed
using Leica Application Suite software, version 2.3.4.R2.
As for mast cell analysis, 1610
6 CFSE-labeled BMMCs were
directly injected into tumor tissue with multiple injection sites. The
mice received i.p. injection of 100 mg of goat-anti-mouse IL-9
neutralizing antibody (R&D Systems) or isotype control 24 h
before and 2 days and 5 days after BMMCs injection. The tumor
tissues were surgically excised at different time points for
fluorescent analysis of frozen sections.
Analysis of Gene Expression by Real-Time RT-PCR
Total RNA was extracted from cells with TRIzol reagent
(Invitrogen, Carlsbad, CA) or from tissues homogenized in TRIzol
according to the manufacturer’s instructions. For real time RT-
PCR assays, the primers were designed with the Oligo Primer
Analysis 4.0 software and the sequences were blasted (http://
www.ncbi.nlm.nih.gov/BLAST/). 100 ng of total RNA was used
for reverse transcription using Superscript II RNase H reverse
transcriptase (Invitrogen) in a volume of 25 ml. Then 2 ml of cDNA
was amplified with SYBR Green Universal PCR Mastermix (Bio-
Rad, Richmond, CA) in duplicate. For sample analysis, the
threshold was set based on the exponential phase of products, and
CT value for samples was determined. The resulting data were
analyzed with the comparative CT method for relative gene
expression quantification against house keeping gene GAPDH.
Western Blot Analysis
Cell lysates or tumor tissue homogenates (30 mg of total protein)
and prestained molecular weight markers were separated by SDS-
PAGE followed by transfer onto nitrocellulose membranes. The
membranes were blocked in TBST (Tris-buffered saline with 0.5%
of Triton X-100) containing 5% nonfat milk, and probed with
primary antibodies. After incubation with the secondary antibody
conjugated with horseradish peroxidase, membranes were exten-
sively washed, and the immunoreactivity was visualized by
enhanced chemiluminescence according to the manufacturer’s
protocol (ECL kit, Santa Cruz, Santa Cruz, CA). All antibodies
were purchased from Santa Cruz (Santa Cruz, CA).
Enzyme-Linked Immunoadsorbent Assay (ELISA)
For the assays of IL-10, IL-13, CCL2, CCL17, and CCL22,
tumor tissues were homogenized in PBS (0.5 ml) containing
100 mm PMSF (Sigma), 1% (vol/vol) aprotinin (Sigma), 2 mg/ml
leupeptin (Sigma), and 1 mg/ml pepstatin (Sigma). After centrifu-
gation, the supernatant was assessed by ELISA kits (R & D
Systems). For, IL-9 ELISA assay, the isolated Treg cells from
tumor tissue were cultured in 96-plate well. 24 hr later, the
supernatant was assessed by ELISA kits (R & D Systems).
Flow Cytometric Analysis
The isolated tumor-infiltrating lymphocytes were stained with
FITC-conjugated rat-anti-mouse Gr-1 and PE-Cy7-conjugated
rat-anti-mouse CD11b for the analysis of MDSCs, or with PE-
Cy7-conjugated hamster-anti-mouse CD3 and FITC-conjugated
rat-anti-mouse Foxp3 for the analysis of Treg cells. All
fluorophore-conjugated Abs and the corresponding isotypes were
purchased from eBioscience. The stained cells were used for flow
cytometric analysis (BD LSR II).
For intracellular staining, after cellular surface staining cells
were fixed and permeabilized with Fix/Perm solution
(eBioscience). The cells were then resuspended in Perm buffer
and incubated with APC-labeled anti-mouse IL-17 antibody or
FITC-conjugated rat-anti-mouse Foxp3 (eBioscience) at room
temperature in the dark for 20 min.
MDSC Suppression Assay
To assess the suppressive activity of MDSCs, splenic T cells
were isolated from spleen of naı ¨ve mice with T cell-enrichment
column (R & D systems). The isolated T cells (2610
4) were
cultured with irradiated MDSCs at different ratios in the presence
of irradiated splenocytes (5610
4) and anti-CD3 antibody (1 mg/
ml) in 96-well microplates. [
3H]thymidine was added during the
last 10 hours of 72-hour culture for the determination of T cell
proliferation.
Treg Cell Suppression Assay
Naı ¨ve splenic T cells were used as responder cells. A total of
2610
4 responder cells were co-cultured with isolated Treg cells at
different ratio for 3 days in the presence of 5610
4 irradiated APCs
(splenocytes) and anti-CD3 (1 mg/ml). [
3H]thymidine was added
during the last 10 hours of 72-hour culture.
Statistics
Results were expressed as mean value 6 SD and interpreted by
ANOVA-repeated measure test. Differences were considered to be
statistically significant when P,0.05.
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